Tiragolumab

Phase 3Monoclonal antibody

Tiragolumab is being investigated as a cancer treatment that works by helping the immune system recognize and attack cancer cells more effectively.[1] Tiragolumab is currently being investigated across 23 indications[3], with its most advanced program in Phase 3.[1]

Tiragolumab is one of 591 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

590

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaActive, not recruiting

Esophageal CarcinomaActive, not recruiting

Esophageal CancerActive, not recruiting

LymphomaActive, not recruiting

AdenocarcinomaActive, not recruiting

Triple-Negative Breast CancerActive, not recruiting

Liver CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Esophageal AdenocarcinomaActive, not recruiting

Metastatic Colorectal CancerActive, not recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Active, not recruiting

Esophageal CarcinomaPhase 3

Active, not recruiting

Esophageal CancerPhase 1/Phase 2

Active, not recruiting

LymphomaPhase 1/Phase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Triple-Negative Breast CancerPhase 1

Active, not recruiting

Liver CancerPhase 1/Phase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1/Phase 2

Active, not recruiting

Esophageal AdenocarcinomaPhase 2

Active, not recruiting

Metastatic Colorectal CancerPhase 2

Active, not recruiting

Showing 10 of 23 indications

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tiragolumab

Roche

Phase 3

1 2

Tecentriq

Roche

Preclinical

36 3

Tykerb

GSK

Preclinical

80 4

Trodelvy

Gilead

Preclinical

37 5

Halaven

Eisai

Preclinical

38 6

Adriamycin

GGynecologic Oncology Group

Preclinical

87 7

Avastin

BBio-Thera Solutions

Preclinical

153 8

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 9

Prolia

Amgen

Preclinical

14 10

Gemzar

GGynecologic Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 3Active, not recruiting

Hepatocellular Carcinoma

NCT05904886

Phase 3Active, not recruiting

Non-Small Cell Lung Cancer

NCT04294810

Q4 2026

Phase 2Active, not recruiting

Renal Cell Carcinoma

NCT05805501

Phase 2Active, not recruiting

Immunotherapy

NCT05798663

Phase 2Recruiting

Squamous Cell Carcinoma

NCT05681039

Phase 2Active, not recruiting

Locally-Advanced Rectal Cancer

NCT05009069

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer9 trials

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2·NCT03563716·135 enrolled

A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)

Completed· Roche logo

Roche·Phase 3·NCT04513925·829 enrolled

A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 2/3·NCT04619797·542 enrolled

Show 6 more trials

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Terminated·LLiza Villaruz, MD·Phase 2·NCT05746481·3 enrolled

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04832854·50 enrolled

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy

Completed· Roche logo

Roche·Phase 3·NCT06267001·56 enrolled

A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03337698·314 enrolled

Neoadjuvant TiRagolumab, Atezolizumab and Chemotherapy - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing: a Non-randomized, Open-label, Single-arm Phase II Study

Active, not recruiting·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT05825625·35 enrolled

SKYSCRAPER-01: Atezolizumab + Tiragolumab in NSCLC

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04294810·800 enrolled

Squamous Cell Carcinoma5 trials

Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Recruiting·AAlain Algazi·Phase 2·NCT03708224·55 enrolled

STRIVE: A Single-arm Phase 2 Study on Treatment of Lung Squamous Cell Carcinoma by Tiragolumab Plus Ivonescimab for Patients Who Progressed on Platinum Doublets and Anti-PD-1/PD-L1

Withdrawn·MM.D. Anderson Cancer Center·Phase 2·NCT07038915

A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent/Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck

Completed· Roche logo

Roche·Phase 2·NCT04665843·123 enrolled

Show 2 more trials

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT05459129·12 enrolled

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05681039·29 enrolled

Small Cell Lung Cancer3 trials

A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small Cell Lung Cancer

Terminated· Roche logo

Roche·Phase 2·NCT04308785·24 enrolled

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04665856·123 enrolled

A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer

Completed· Roche logo

Roche·Phase 3·NCT04256421·490 enrolled

Metastatic Colorectal Cancer3 trials

Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06603818

Trial of Atezolizumab, Bevacizumab, and Tiragolumab in Patients With Microsatellite Stable, Metastatic Colorectal Cancer

Active, not recruiting·UUniversity of Colorado, Denver·Phase 2·NCT06784947·13 enrolled

A Phase I/Ib Global, Multicenter, Open-label Umbrella Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)

Recruiting· Roche logo

Roche·Phase 1·NCT04929223·542 enrolled

Melanoma3 trials

Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection

Terminated·WWashington University School of Medicine·Phase 2·NCT05060003·7 enrolled

Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma

Active, not recruiting·MMayo Clinic·Phase 2·NCT03554083·59 enrolled

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Completed· Roche logo

Roche·Phase 1/2·NCT05116202·110 enrolled

34 more indications

Urothelial Carcinoma2 trials

Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial Carcinoma

Recruiting·MM.D. Anderson Cancer Center·Phase 1/2·NCT05394337·10 enrolled

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Completed· Roche logo

Roche·Phase 1/2·NCT03869190·272 enrolled

Advanced Solid Tumors2 trials

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT03977467·46 enrolled

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

Completed· Roche logo

Roche·Phase 2·NCT04632992·252 enrolled

Hepatocellular Carcinoma2 trials

A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

Active, not recruiting· Roche logo

Roche·Phase 3·NCT05904886·687 enrolled

A Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma

Completed· Roche logo

Roche·Phase 1/2·NCT05908786·62 enrolled

Breast Cancer1 trial

NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial

Recruiting·TThe Netherlands Cancer Institute·Phase 2·NCT06342037·60 enrolled

Locally Advanced1 trial

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Unknown status·NNational Taiwan University Hospital·Phase 1/2·NCT05743504·32 enrolled

Esophageal Cancer1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03281369·214 enrolled

Locally-advanced Rectal Cancer1 trial

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05009069·58 enrolled

Cervical Cancer1 trial

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer

Completed· Roche logo

Roche·Phase 2·NCT04300647·172 enrolled

Metastatic Tumors1 trial

Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors

Completed· Roche logo

Roche·Phase 1·NCT02794571·518 enrolled

Stereotactic Body Radiation Therapy1 trial

Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)

Unknown status·CCentre Georges Francois Leclerc·Phase 1·NCT05259319·92 enrolled

Immunotherapy1 trial

Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLC

Active, not recruiting·AAlliance Foundation Trials, LLC.·Phase 2·NCT05798663·178 enrolled

Esophageal Squamous Cell Carcinoma1 trial

A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy

Active, not recruiting· Roche logo

Roche·Phase 3·NCT04543617·760 enrolled

Recurrent or Metastatic Solid Tumors1 trial

A Study to Evaluate the Safety and Pharmacokinetics of the Intravenous Fixed-Dose Combination (IV FDC) of Tiragolumab and Atezolizumab in Participants With Locally Advanced, Recurrent or Metastatic Solid Tumors

Completed· Roche logo

Roche·Phase 2·NCT05661578·64 enrolled

Advanced1 trial

Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients

Recruiting·OOmico·Phase 2·NCT06003621·96 enrolled

Gastroesophageal Junction Carcinoma1 trial

An Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Gastric or Gastroesophageal Junction Carcinoma

Completed· Roche logo

Roche·Phase 1/2·NCT05251948·40 enrolled

Adenocarcinoma1 trial

A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)

Terminated· Roche logo

Roche·Phase 2·NCT04933227·29 enrolled

Triple-Negative Breast Cancer1 trial

A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer

Completed· Roche logo

Roche·Phase 1·NCT04584112·83 enrolled

Metastatic Urothelial Cancer1 trial

A Study Evaluating Different Immunotherapies (LAG-3 and PD-1 With or Without TIGIT, Compared to PD-L1 Alone) in Participants With Untreated Locally Advanced Metastatic Urothelial Cancer

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05645692·204 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Microsatellite Instability1 trial

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)

Withdrawn· Roche logo

Roche·Phase 2·NCT06331598

Glioblastoma1 trial

Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT06328036

Relapsed or Refractory1 trial

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 1/2·NCT05286801·86 enrolled

Advanced Solid Malignancies1 trial

Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06760481·7 enrolled

Advanced Stage1 trial

Testing the Combination of Anti-cancer Drugs Atezolizumab and Tiragolumab in People With Advanced Stage Rare Cancers, RARE3 Trial

Active, not recruiting·NNational Cancer Institute (NCI)·Phase 2·NCT05715281·12 enrolled

Immune Checkpoint Inhibition1 trial

A Phase 2 Clinical Trial Evaluating the Efficacy and Safety of Dual Immune Checkpoint Inhibition With Anti-PD-L1 (Atezolizumab) and Anti-TIGIT (Tiragolumab) in Cancer of Unknown Primary

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT06754501·4 enrolled

Renal Cell Carcinoma1 trial

A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participants With Untreated Locally Advanced Unresectable or Metastatic Renal Cell Carcinoma

Active, not recruiting· Roche logo

Roche·Phase 2·NCT05805501·199 enrolled

Esophageal Adenocarcinoma1 trial

Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal Adenocarcinoma

Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03784326·43 enrolled

Esophageal Carcinoma1 trial

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

Completed· Roche logo

Roche·Phase 3·NCT04540211·461 enrolled

Multiple Myeloma1 trial

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Terminated· Roche logo

Roche·Phase 1·NCT04045028·41 enrolled

Non-squamous NSCLC1 trial

Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC

Active, not recruiting·GGeorgetown University·Phase 2·NCT04958811·29 enrolled

Endometrial Cancer1 trial

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

Recruiting·AAlliance Foundation Trials, LLC.·Phase 1/2·NCT04486352·148 enrolled

Lymphoma1 trial

An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma

Terminated· Roche logo

Roche·Phase 1/2·NCT05315713·8 enrolled

Advanced Liver Cancers1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Recruiting· Roche logo

Roche·Preclinical·NCT04524871·518 enrolled

Unspecified1 trial

An Open-Label, Multicenter Extension Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Study

Recruiting· Roche logo

Roche·Phase 3·NCT05862285·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 60 trial records for Tiragolumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tiragolumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tiragolumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Roche company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: T-Cell Immunoreceptor With Ig and ITIM Domains Inhibitor[2]
Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: Roche

Tiragolumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Non-Small Cell Lung Cancer9 trials

Squamous Cell Carcinoma5 trials

Small Cell Lung Cancer3 trials

Metastatic Colorectal Cancer3 trials

Melanoma3 trials

Urothelial Carcinoma2 trials

Advanced Solid Tumors2 trials

Hepatocellular Carcinoma2 trials

Breast Cancer1 trial

Locally Advanced1 trial

Esophageal Cancer1 trial

Locally-advanced Rectal Cancer1 trial

Cervical Cancer1 trial

Metastatic Tumors1 trial

Stereotactic Body Radiation Therapy1 trial

Immunotherapy1 trial

Esophageal Squamous Cell Carcinoma1 trial

Recurrent or Metastatic Solid Tumors1 trial

Advanced1 trial

Gastroesophageal Junction Carcinoma1 trial

Adenocarcinoma1 trial

Triple-Negative Breast Cancer1 trial

Metastatic Urothelial Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Microsatellite Instability1 trial

Glioblastoma1 trial

Relapsed or Refractory1 trial

Advanced Solid Malignancies1 trial

Advanced Stage1 trial

Immune Checkpoint Inhibition1 trial

Renal Cell Carcinoma1 trial

Esophageal Adenocarcinoma1 trial

Esophageal Carcinoma1 trial

Multiple Myeloma1 trial

Non-squamous NSCLC1 trial

Endometrial Cancer1 trial

Lymphoma1 trial

Advanced Liver Cancers1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News